Clinical trial started for treatment of mild and moderate corona infected patients in US

Washington, ANI. Clinical trials have begun in the US for the treatment of mild and moderately infected cornea patients. The US National Institutes of Health (NIH) reported on Tuesday that a Phase II trial has begun in the US to evaluate a potential therapeutic safety for corona and its efficacy. This clinical trial involves a clinical trial based on synthetic monoclonal antibodies (mAbs) for the treatment of corona.

Researchers are working with clinical sites sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). He is working on potential volunteers who are currently infected with Korana. According to a NIH release, mild to moderate corona patients do not require hospitalization for treatment.

Mild and moderate corona-infected patients will be invited to take medical therapy or a placebo as part of a rigorously designed clinical. This test is known as ACTIV-2. The latter may also examine other experimental treatments under the same testing protocol.